Follow us on Twitter
twitter icon@FreshPatents


Autoimmune Disease patents

      

This page is updated frequently with new Autoimmune Disease-related patent applications.




 Method and kit for the predictive prognosis of responsiveness to treatments of autoimmune diseases patent thumbnailMethod and kit for the predictive prognosis of responsiveness to treatments of autoimmune diseases
The present invention relates to the use of one or more mhc class i molecules dextramers (dextramers®) associated with peptides corresponding to apoptotic epitopes of human cd8+ t cells for the predictive prognosis of responsiveness or non-responsiveness to treatments and/or for monitoring the therapeutic effectiveness of treatments with biological medicaments that block and/or inhibit tnf, and/or biological medicaments that block and/or inhibit cytokines or cytokine receptors and/or biological medicaments against b cells and/or biological medicaments that inhibit t cell co-stimulation in patients affected by autoimmune diseases, together with methods and kits for said predictive prognosis.. .
Universita' Degli Studi Di Roma "la Sapienza"


 Oral administration of an anti-cd20 antibody for treatment of autoimmune disease patent thumbnailOral administration of an anti-cd20 antibody for treatment of autoimmune disease
The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of an anti-cd20 antibody is administered to the subject.

 Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions patent thumbnailCompositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory t cells (treg) populations; for treating or ameliorating a vascular inflammation, and kawasaki disease (kd) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them. Provided are immunotherapies for promoting expansion of natural, treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (wig) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a t cell mediated pediatric vasculitis; kawasaki disease (kd) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or juvenile idiopathic arthritis; a neoplastic hematological disorder, or a leukemia..
The Regents Of The University Of California


 Indole carboxamide compounds patent thumbnailIndole carboxamide compounds
Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

 Pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis and  treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis patent thumbnailPharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis and treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis
The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging to rutaceae as an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, crohn's disease and ulcerative colitis (uc).. .
Industrial Technology Research Institute


 Methods and compositions for modified t cells patent thumbnailMethods and compositions for modified t cells
The present invention relates to compositions and methods for generating modified cells with nucleic acid encoding a t cell receptor (tcr), a nucleic acid encoding a bispecific antibody, affinity molecule chimeric receptor, bispecific affinity molecule, or a chimeric ligand engineered activation receptor (clear). One aspect includes a method for generating a modified t cell.
The Trustees Of The University Of Pennsylvania


 Fgl2 expressing regulatory t cells patent thumbnailFgl2 expressing regulatory t cells
This application relates to methods and compositions for inducing immune tolerance. Specifically, methods and uses of regulatory t cells (treg) and associated compositions for the induction of immune tolerance are described.
Veritas Therapeutics Inc.


 Therapeutic detoxification compositions and methods of making and using same patent thumbnailTherapeutic detoxification compositions and methods of making and using same
A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.. .
Immutrix Therapeutics, Inc.


 Treatments for autoimmune disease patent thumbnailTreatments for autoimmune disease
The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases.
The Provost, Fellows, Foundation Scholars, And The Other Members Of Board,of The College Of The Holy


 Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor patent thumbnailPharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc


Method for the detection of antigen presentation

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule.
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Novel imidazopyridazine compounds and their use

This disclosure provides novel imidazopyridazine compounds of formula (i) and pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their practical effect in inhibiting pi3k and potential use in treating a disease responsive to inhibition of pi3k, for example, an inflammatory disease, autoimmune disease or cancer.. .
Hutchison Medipharma Limited

Probiotic bifidobacterium adolescentis strains

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated with human pbmc derived dendritic cells. The strains may have one, two or all three of these capabilities.
Chr. Hansen A/s

Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases

The embodiments herein relate to a therapeutic method for the treatment of parkinson disease, other neurodegerative disorders, and autoimmune diseases. The method includes providing sodium thiosulfate through any method of administration (orally, intravenously, through inhalation, intravesically, vaginally, rectal route, sublingually, ophthalmically, or topically) and is given with one or more pharmaceutically acceptable carriers or excipients.

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Modulation of ptpra to treat arthritis

Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (pt-pra) antagonist.. .
The Regents Of The University Of California

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment.
Biogen Ma, Inc.

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Targeted delivery of tertiary amine-containing drug substances

Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed..
Seattle Genetics, Inc.

(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability

The invention relates to solid pharmaceutical compositions comprising (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.. .
Sanofi

Concentrated methotrexate solutions

Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh

Anti-pd-1 monoclonal antibody and obtaining method therefor

The invention provides human monoclonal antibodies that specifically bind to pd-1 with high affinity. The anti-pd-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed.
Beijing Jingyitaixiang Technology Development Co., Ltd.

Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28

Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human cd28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody.
Bristol-myers Squibb Company

Modulating gamma-c-cytokine activity

Peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Y is c, n or s.. .

Compounds that expand hematopoietic stem cells

The present invention relates to compounds and compositions for expanding the number of cd34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (hscs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense..
Novartis Ag

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions

Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
Caliper Life Sciences, Inc.

Methods and kits for screening transplant recipients and candidates

Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease.
National Institute Of Transplantation Foundation

Antibodies specific for mmp9

The present invention relates to new proteins that bind to mmp9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the mmp9 binding proteins according to the invention are able to neutralize mmp9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers.
Merck Patent Gmbh

Anti-cd40 antibodies and uses thereof

Antibodies and antibody fragments that bind to human cd40 and inhibit interaction between cd40 and its ligand, cd40l are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit hyperactivation of b or t cells and treat or prevent disorders such as autoimmune diseases..
Biogen Ma Inc.

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Flt3 receptor antagonists

The invention pertains to novel flt3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases..
UniversitÉ De Strasbourg

Soluble mediator

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..
The Walter And Eliza Hall Institute Of Medical Research

Aza-heteroaryl compounds as pi3k-gamma inhibitors

And pharmaceutically acceptable salts thereof, wherein x, y, z, a, w, r4, r5, and r6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

Treatment of ocular inflammatory diseases using laquinimod

Disclosed is a method for treating an ocular inflammatory disease (oid), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an oid, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.
Teva Pharmaceutical Industries, Ltd.

Supporting immunomodulatory agent

The invention relates to an agent supporting the immunomodularity for the treatment of autoimmune diseases, said agent containing c3-c8 carboxylic acids, their physiologically tolerable salts and/or esters with c1-c8 alkyl alcohols, their use as supporting immunomodulators for autoimmune related diseases and immune-mediated chronic inflammatory diseases, as well as dietary supplements with immunomodulating effect containing these.. .
Flexopharm Brain Gmbh & Co. Kg

Aptamers for use against autoantibody-associated diseases

The present invention relates to new aptamer molecules for use in the treatment and/or diagnosis of autoimmune diseases associated with autoantibodies against g-protein coupled receptors, a pharmaceutical composition comprising such aptamer molecules, an apheresis column comprising such aptamer molecules and a method for the determination of nucleotide sequences for use as sequences of aptamer molecules.. .
Berlin Cures Holding Ag

Antibody therapeutics that bind cd137

There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

An anti-cd45rc antibody for use as drug

The invention relates to an isolated anti-cd45rc antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with cd45rc+ cells. The invention relates to an isolated anti-cd45rc antibody for use in expanding and/or potentiating regulatory t cells..
UniversitÉ De Nantes

Therapeutic use of anti-cd22 antibodies for inducing trogocytosis

Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-b cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention.
Immunomedics, Inc.

Modified peptides and their use for treating autoimmune diseases

The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications.. .
Immupharma France Sa

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Discovery of regulatory t cells programmed to suppress an immune response

A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (il-15r) agonists in an amount effective to ameliorate a symptom of the autoimmune disease.
Dana-farber Cancer Institute, Inc.

Tropomyosin-related kinase (trk) inhibitors

Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation

Methods of treating inflammatory and autoimmune diseases and disorders

Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder.
Yale University

Her2/neu-specific antibodies and methods of using same

This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Methods for treating thrombosis using chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Immunoglobulin constant region fc receptor binding agents

Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function.
Gliknik Inc.

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution

Automated immunoanalyzer system for performing diagnostic assays for allergies and autoimmune diseases

A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Use of pdl1 expressing cells to convert t cells into regulatory t cells

The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Antibody binding to fcrn for treating autoimmune diseases

The present disclosure relates to an isolated anti-fcrn antibody, which is an antibody binding to fcrn (stands for neonatal fc receptor, also called fcrp, fcrb or brambell receptor) that is a receptor with a high affinity for igg or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The fcrn-specific antibody according to the present disclosure binds to fcrn non-competitively with igg to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.

Antibody binding to fcrn for treating autoimmune diseases

The present disclosure relates to an isolated anti-fcrn antibody, which is an antibody binding to fcrn (stands for neonatal fc receptor, also called fcrp, fcrb or brambell receptor) that is a receptor with a high affinity for igg or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The fcrn-specific antibody according to the present disclosure binds to fcrn non-competitively with igg to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.

Composition containing smad protein for treatment of autoimmune diseases, a fusion protein comprising smad protein, an expression vector and a preparing the same

The present invention relates to a composition and a fusion protein for prevention or treatment of autoimmune diseases, which contain a smad protein, and provides a method for prevention or treatment of autoimmune diseases, including lupus nephritis and rheumatoid arthritis.. .

Pegylated interferon-beta variant

The present invention provides a pegylated ifn-β variant and a composition for preventing or treating hyperproliferative diseases, inflammatory diseases, autoimmune diseases or viral infectious diseases, the composition comprising the pegylated ifn-β variant as an effective ingredient. The pegylated ifn-β variant of the present invention has an excellent anti-viral efficacy, immune regulatory function and anti-cell growth efficacy by virtue of better pharmacokinetic properties compared to native ifn-β and non-pegylated ifn-β variants, and therefore can be used usefully against various diseases.
Abion Inc.

Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same

The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and pge2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of nr4a2 and/or ubash3b at gene or protein are increased more than 2-fold compared to the immature dendritic cells in addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy..
Jw Creagene Inc.

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Molecules with specificity for cd45 and cd79

The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen cd45 and a binding domain specific to the antigen cd79a and/or cd79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.. .
Ucb Biopharma Sprl

Anti-ilt7 antibody

An antibody binding to ipc was obtained by using an animal cell in which a cell membrane protein associatable with ilt7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ilt family molecules and ilt7.
Sbi Biotech Co., Ltd.

Molecules with specificity for cd79 and cd22

The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen cd22 and a binding domain specific to the antigen cd79a and/or cd79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.. .
Ucb Biopharma Sprl

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein using a linker. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Method of designing a peptide and/or peptide derivative for modulating gamma-c-cytokine activity

The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

The invention relates to an isolated interleukin-34 (il-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of il-34 in a biological sample obtained from said patient, wherein the presence of il-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies..
UniversitÉ De Nantes

Small molecule inhibitors of stat3 with anti-tumor activity

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s3i-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
University Of Central Florida Research Foundation.

Marker sequences for diagnosing and stratifying systemic sclerosis patients

The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; ssc) and to the markers identified with the aid of this method, which can differentiate between ssc and other autoimmune diseases on the one hand and between different ssc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of ssc.
Protagen Ag

Compositions and methods for the diagnosis of systemic autoimmune disease

The present disclosure relates to the field of molecular biology and immunology. More specifically, the present disclosure provides compositions and methods for detecting anti-th/to autoantibodies in the serum of subject with a systemic autoimmune disease, such as systemic sclerosis (ssc)..
Inova Diagnostics, Inc.

Methods of using cells associated with autoimmune disease

The present invention relates to methods of diagnosing autoimmune disease, predicting suitable treatments of autoimmune disease or identifying autoantigens of autoimmune disease using a population of immunogenic hla-dr+ t cells.. .
Singapore Health Services Pte Ltd.

Novel combinations for antigen based therapy

The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject the subject may have a serum vitamin-d level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years. The invention also relates to a composition comprising a plurality of particles, each having immobilised on its surface at least one first and at least one second antigen, wherein the first antigen is a beta cell autoantigen, and the second antigen is either a tolerogen or a beta cell autoantigen, and to composition comprising i) at least one beta cell autoantigen, and at least one of iia) an il-10 inducing compound selected from the group consisting of vitamin-d, vitamin-d analogs, tyrosine kinase inhibitors, gamma-amino butyric acid, and gamma-amino butyric acid analogs; and iib) a compound that reduces the dendritic cells' ability to activate naïve cd4+ tcells, such as a cyclooxygenase inhibitor, a ctla-4 compound or a tnf alpha inhibitor.
Diamyd Medical Ab

Mth1 inhibitors for treatment of inflammatory and autoimmune conditions

A compound of formula (i), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.. .
Thomas Helledays Stiftelse For Medicinsk Forskning

Treatment of autoimmune disease

Provided herein are compositions and methods for the treatment of autoimmune diseases, including lupus, uveitis and encephalitis. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole pkc inhibitors..
Mingsight Pharmaceuticals, Inc.

Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases

The specification provides compositions comprising chimeric proteins comprising aat conjugated to an fc region of an immunoglobulin. Methods for treating autoimmune disease, e.g., diabetes, e.g., type 1 and type 2 diabetes, are also provided..
Beth Israel Deaconess Medical Center, Inc.

Pyridine and pyridimine compounds as pi3k-gamma inhibitors

The present disclosure provides compounds of formula i, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .
Incyte Corporation

Use of kukoamine a and kukoamine b

The use of kukoamine a and kukoamine b in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (lps) and unmethylated dna (cpg dna) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use and directionally isolates lead compounds from traditional chinese medicine.
The First Affiliated Hospital, Third Military Medical University, Pla

Dd1alpha receptor and uses thereof in immune disorders

Described herein are methods and compositions for treatment of immune-related diseases or disorders by modulating dd1α activity, alone or in combination with modulation of pd-1 activity. In some embodiments, the methods and compositions described herein are directed to treatment of cancer and/or infections (e.g., bacterial infection, and/or fungal infection).
The General Hospital Corporation

Compositions and methods for autoimmune disease

Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (scnp), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease.. .
Nodality, Inc.

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Pyrrolopyrimidine compounds and their uses

The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases.
Astex Therapeutics Ltd.

Autoantibody detection method, testing possibility of autoimmune disease contraction, autoantibody detection reagent, and autoimmune disease test reagent

The present invention provides an autoantibody detection method that can detect an autoantibody causing an autoimmune disease with high accuracy. The autoantibody detection method of the present invention includes the steps of; causing a sample and an antigen reagent comprising a denatured protein presented by an mhc class ii molecule to come into contact with each other; and detecting a complex of an autoantibody in the sample and the denatured protein in the antigen reagent.
Osaka University

Self assembling nucleic acid nanostructures

Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of g-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of g-quadruplex stabilizing domains linked to the g-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as toll-like receptors; for inhibiting dna or rna expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases..
Exicure, Inc.

Bi-terminal pegylated integrin-binding peptides and methods of use thereof

The present invention provides bi-terminal pegylated peptide conjugates that target an integrin such as αvβ6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the peg moieties.
The Regents Of The University Of California

Quinoxaline compounds and uses thereof

This invention provides compounds of formula i and subsets thereof: wherein t, j, r, r4, rq, o, ra, and rb and subsets thereof are as described in the specification. The compounds are inhibitors of nampt and are thus useful for treating cancer, inflammatory conditions, or t-cell mediated autoimmune disease..
Millennium Pharmaceuticals, Inc.

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds described herein, such as of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Binding molecules specific for il-21 and uses thereof

This disclosure provides il-21 binding molecules, e.g., anti-il-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-il-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof.
Boston Pharmaceuticals Inc.

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity

The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.
University-industry Cooperation Group Of Kyung Hee University

Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory t cells

The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory t cells (treg) in an organism and various methods in which the agents according to the invention are used.. .
Aicuris Gmbh & Co. Kg

Har-nds-derived stem cells, separating same, and use thereof

The present invention relates to hyaluronic acid-rich node and duct system (har-nds)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (ndscs), which are adult stem cells having an ability to differentiate into har-nds-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from har-nds, adult stem cells ndscs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases..
Eutilex Co., Ltd

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.
Platform Brightworks Two, Ltd.

Benzo lipoxin analogues

Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation..
University Of Southern California

Canine autoimmune conditions and diagnosis and treatment thereof

The disclosure includes methods of identifying a dog at risk of developing a an autoimmune disease or condition, for example a hypothyroid disease or condition, comprising testing whether the dog exhibits one or more selected single nucleotide polymorphisms (snps), together with diagnostic kits for carrying out such methods, methods of treatment or prophylaxis of such autoimmune disease or condition, e.g., comprising administering an effective amount of tea extract to a dog in need thereof, and a canine diet or supplement comprising tea extract, useful for treatment of prophylaxis of such autoimmune disease or condition, or for maintenance of thyroid health in a dog.. .
The Translational Genomics Research Institute

Humanized antibodies against cd269 (bcma

The invention relates to humanized antibodies or antibody fragments that bind cd269 (bcma), thereby disrupting the interaction between cd269 and its native ligands (baff and april), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.. .
Max-delbruck-centrum Fur Molekulare Medizin In Der Helmholtz-gemeinschaft

O-glcnac transferase (ogt) inhibitors and uses thereof

The present invention provides inhibitors of o-glcnac transferase. Typically, the inhibitors are quinolinone-6-sulfonamides.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Methods to treat diseases with protein, peptide, antigen modification and hemopurification

The current invention discloses methods to modify protein and peptide and antigen to treat disease such as pathogen infection, autoimmune diseases and cancer. The method involves increasing the molecular weight of the protein by connecting multiple peptide units with site specific conjugation to extend the in vivo half life.

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity

The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.
University-industry Cooperation Group Of Kyung Hee University

Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory t cells

The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory t cells (treg) in an organism and various methods in which the agents according to the invention are used.. .
Aicuris Gmbh & Co. Kg

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof

The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (ia) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
Arena Pharmaceuticals, Inc.

Compositions and methods for modulation of rorgammat functions

The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response.

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-cd20 antibodies for treatment of cd20 positive malignancies and autoimmune diseases.. .
Genentech, Inc.

Ip-10 antibodies and their uses

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Bristol-myers Squibb Company

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Protein kinase inhibitors

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the tec or src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated..
Pharmascience Inc.

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
The Walter And Eliza Hall Institute Of Medical Research

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, y, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Composition using metformin for preventing or treating immune diseases including lupus

The present invention relates to a composition for preventing or treating immune diseases through the suppression of b cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of b cell activity which is a cause of disease.
Catholic University Industry Academic Cooperation Foundation

Anti-cd19 antibodies

The present invention provides humanized, chimeric and human anti-cd19 antibodies, anti-cd19 antibody fusion proteins, and fragments thereof that bind to a human b cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various b-cell disorders, including b-cell malignancies and autoimmune diseases.
Immunomedics, Inc.

Aminopyridazinone compounds as protein kinase inhibitors

The present disclosure provides a compound of formula (i) and the use thereof for the therapeutic treatment of human cancers including b-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.. .
Eternity Bioscience Inc.

Tetrahydroisoquinolinone derivatives and their use in the inhibition of the hsp70 protein

The present invention relates to tetrahydroisoquinolinone derivatives, a pharmaceutical composition comprising the same and the use of these derivatives in the inhibition of the hsp70 protein. The compounds are useful in the treatment or inhibition of cancer, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease and psoriasis..
Julius-maximilians-universitaet Wuerzburg

Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases

Disclosed herein are compositions and methods of use comprising combinations of anti-cd22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-cd22 antibody or may be separately administered, either before, simultaneously with or after the anti-cd22 antibody.
Immunomedics, Inc.

Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo

The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.. .
Applied Molecular Transport Llc

Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response

The present invention relates to the use of leukotriene b4 to enhance the response of toll-like receptor (tlr), rig-i-like receptor (rlr), and nod-like receptor (nlr) when stimulated simultaneously with respective proper ligands. The use in combination of ltb4 with those ligands is useful to potentiate immune response for the treatment of autoimmune diseases, immunosuppressive diseases, as well as immunological disorders..
Universite De Laval

Genetic polymorphisms associated with rheumatoid arthritis, metods of detection and uses thereof

The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection..

Use of mcoln-1 modulators to regulate cell migration

The present invention relates to the use of modulators of mcoln-1 for modulating the cells migration, in particular the migration of dendritic cells and tumor cells, especially for antitumoral vaccination, autoimmune diseases treatment, and metastasis prevention.. .

Inhibitor of bruton's tyrosine kinase

Provided are a compound represented by formula (iii) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (iii), and the application of the pharmaceutical compositions as selective inreversible inhibitor of bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant b cell proliferation and cancers.. .

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring mechanism

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

Rituximab induction therapy followed by glatiramer acetate therapy

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, crohn's disease, or systemic lupus erythematosus..

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .

Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate

In an embodiment, therapeutic methods and uses of bruton's tyrosine kinase (btk) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on btk occupancies and/or btk resynthesis rates for b cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for a btk inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on btk occupancies and/or btk resynthesis rates for b cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described..

Antibodies to il-15

The present invention relates to antibodies binding il-15, in particular humanized antibodies. In particular, the anti-il-15 antibodies according to the invention are able to neutralize il-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens..
Calypso Biotech Sa

Kv1.3 potassium channel antagonists

The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel kv1.3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection..
Conogenetix Biosciences Gmbh

Treatment of autoimmune diseases with deep brain stimulation

Techniques using electrical stimulation for treating an autoimmune disease by means of an implantable pulse generator and at least one electrode. An electrode lead is surgically implanted in a region of the insular cortex to deliver electrical stimulation.
Aleva Neurotherapeutics

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasus arteritis

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.. .
Prothena Biosciences Limited

Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine

The present disclosure provides methods for modulating the interaction between a tam ligand and a lipid membrane containing phosphatidyl serine (ptdser). In one example, such methods use a tam receptor agonist having a ptdser-containing lipid bilayer membrane with gas6 and/or protein s bound to the membrane to activate signaling from one or more tam receptors and treat an autoimmune disease.
Kolltan Pharmaceuticals, Inc.

Heterocyclic compounds as pi3k-y inhibitors

Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

Urea derivatives and uses thereof

The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.

Method of isolating sphingolipids from cordyceps and their use

A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from cordyceps, in particular from wild-type cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities.
Macau University Of Science And Technology

Phosphatidylglycerol as an anti-inflammatory

Compositions and methods for reducing, or inhibiting inflammation in a subject in need thereof have been developed. Pharmaceutical compositions including one or more phosphatidylglycerol (pg), or functional derivatives thereof, in an effective amount to reduce or inhibit inflammation are provided.
Agusta University Research Institute, Inc.

Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity

The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity..
Universite D'aix-marseille

Antibody which specifically binds to human crth2

There is provided an anti-human crth2 antibody which has desired activity by recognizing and binding to a specific human crth2; the antibody fragment; dna which encodes the amino acid sequence of the antibody; a vector which comprises the dna; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.. .
Kyowa Hakko Kirin Co., Ltd

Using b-cell-targeting antigen igg fusion as tolerogenic protein therapy for treating adverse immune responses

The present invention generally relates to antigen-specific tolerogenic protein therapy and the use thereof for treating adverse immune responses, including those associated with autoimmune diseases such as multiple sclerosis (ms) and hemophilia. In particular, the invention involves the application of a b cell-targeting igg fusion protein as the antigen-specific tolerogenic protein therapy, either alone or in combination with inhibitory antibodies.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

Amino sphingoglycolipid analogues

The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.. .

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Biotherapeutics, Inc.

Anti-il-2 antibodies and compositions and uses thereof

The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to il-2 and reduce the affinity of il-2 binding to il-2rα and il-2rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same.
The Board Of Trustees Of The Leland Stanford Junior University

Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same

These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting garftase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.. .

Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

The present disclosure provides a compound of formula (i) and the use thereof for the therapeutic treatment of human cancers including b-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.. .
Eternity Bioscience Inc.

Novel compound having immune disease treatment effect and use thereof

The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory t cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Enhanced atra-related compounds derived from structure-activity relationships and modeling for inhibiting pin1

The invention features all-trans retinoic acid (atra)-related compounds capable of associating with pin1 and methods of identifying the same. The invention also provides methods of treating a condition selected from the group consisting of a proliferative disorder, an autoimmune disease, and an addiction condition characterized by elevated pin1 marker levels, pin1 degradation, and/or reduced pin1 ser71 phosphorylation in a subject by administering a retinoic acid compound.
Beth Israel Deaconess Medical Center, Inc.

Methods of treatment of inflammation of the gut

Described herein are methods of improving immune homeostasis in the gut of a subject suffering from an autoimmune disease characterized by inflammation of the gut by administering, e.g., orally administering, to the subject an effective amount of a cannabinoid receptor agonist to improve immune homeostasis in the gut of the subject. Exemplary cannabinoid receptor ligands include anandamide.
The University Of Connecticut

Monomers and oligonucleotides comprising cycloaddition adduct(s)

In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring

Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of tigit, flg2 and/or il-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection).
The Brigham And Women's Hospital, Inc.

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasus arteritis

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.. .
Prothena Biosciences Limited

Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors..
Medimmune Limited

Modulating gamma-c-cytokine activity

Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

Indolin-2-one or pyrrolo-pyridin-2-one derivatives

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, huntington's disease, adhd, amyotrophic lateral sclerosis, epilepsy, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems.. .



Autoimmune Disease topics:
  • Autoimmune Disease
  • Immune Disease
  • Autoimmune
  • Autoimmune Diseases
  • Immune Diseases
  • Transplant
  • Infectious Disease
  • Infectious
  • Inflammatory Disease
  • Antagonist
  • Rheumatoid Arthritis
  • Proliferative
  • Nucleotide
  • Antibodies
  • Infectious Diseases


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.9652

    file did exist - file did put13802

    4 - 1 - 251